Results 41 to 50 of about 70,737 (298)

A randomized, double‐blind clinical trial to evaluate the efficacy and safety of a fixed‐dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension

The Journal of Clinical Hypertension, 2020
This multicenter, randomized, double‐blind, parallel‐group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive ...
Woohyeun Kim, Kiyuk Chang, E. Cho, J. Ahn, C. Yu, K. Cho, Yong‐Jin Kim, D. Kang, Seok-Yeon Kim, Sang-Hak Lee, U. Kim, Shin-Jae Kim, Y. Ahn, C. Lee, J. Shin, Mikyung Kim, C. Park   +16 more
semanticscholar   +1 more source

Impact of Cumin and Green Tea on Amlodipine Pharmacodynamics and Pharmacokinetics in Hypertensive Rats

Separations, 2023
The main purpose of the current research was to determine the impact of cumin and green tea on the pharmacodynamics and pharmacokinetics of amlodipine in hypertensive rats. Wistar rats were given 40 mg/kg of L-NAME orally every day for two weeks in order
Ibrahim Abdelsalam Abdelrahman, Abdul Ahad, Mohammad Raish, Yousef A. Bin Jardan, Mohd Aftab Alam, Fahad I. Al-Jenoobi   +5 more
doaj   +1 more source

Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension

Pharmaceuticals, 2022
Association between calcium channel blockers (CCBs) or functional inhibitors of acid sphingomyelinase (FIASMAs) use and decreased mortality in people with COVID-19 has been reported in recent studies.
Gwenolé Loas, Philippe Van de Borne, Gil Darquennes, Pascal Le Corre   +3 more
doaj   +1 more source

Antidepressive and anxiolytic effects of ostruthin, a TREK-1 channel activator [PDF]

, 2018
We screened a library of botanical compounds purified from plants of Vietnam for modulators of the activity of a two-pore domain K+ channel, TREK-1, and we identified a hydroxycoumarin-related compound, ostruthin, as an activator of this channel ...
Joseph, Ancy, Okada, Masayoshi, Thanh, Le Tat, Thuy, Tran Thi Thu   +3 more
core   +2 more sources

An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial [PDF]

, 2016
Background: Cardiovascular diseases (CVD) are responsible for significant morbidity, premature mortality, and economic burden. Despite established evidence that supports the use of preventive medications among patients at high CVD risk, treatment gaps ...
Adina Hayek, Anthony Rodgers, Antithrombotic Trialists’ Collaboration, Antithrombotic Trialists’ Collaboration, Anushka Patel, B Mitchell, B Patel, Baldeep Kaur, Bandana Saini, BL Carter, BL Svarstad, BL Svarstad, Blood Pressure Lowering Treatment Trialists' Collaboration, C Armour, C Baigent, Carol Armour, Charlotte Hespe, Christopher Reid, D Peiris, D Peiris, D Peiris, David Peiris, DE Morisky, DE Morisky, DM Wentzlaff, DP Peiris, E Hatah, EL Heeley, Fred Hersch, GF Moore, Ines Krass, JK Lee, KL Margolis, Louise Shiel, M Krousel-Wood, MP Morgado, N Houston Miller, P Ho, R Webster, RB Haynes, RJ Webster, Rohina Joshi, Ruth Webster, S Jan, S Michie, Serigne Lo, Stephen Jan, Tim Usherwood, Tracey-Lea Laba, WK Kellogg Foundation, World Health Organisation   +50 more
core   +4 more sources

A possible increase in liver enzymes due to amlodipine: A case report

SAGE Open Medical Case Reports, 2020
Amlodipine is a commonly prescribed antihypertensive drug, well tolerated and has rarely been attributed as a cause for elevated liver enzymes. Here, we present a 47-year-old male patient known to be hypertensive and admitted to our rehabilitation ...
Ginny Varghese, Lama Madi, Muna Ghannam, Rafaat Saad   +3 more
doaj   +1 more source

Generic versus brand-name drugs used in cardiovascular diseases [PDF]

, 2016
This meta-analysis aimed to compare the efficacy and adverse events, either serious or mild/moderate, of all generic versus brand-name cardiovascular medicines.
Boccia, Stefania, D'Andrea, Elvira, Flacco Maria, Elena, Ioannidis John, Pa, Manzoli, Lamberto, Marzuillo, Carolina, Panic, Nikola, Ricciardi, Walter, Siliquini, Roberta, Villari, Paolo   +9 more
core   +1 more source

Amlodipine-induced gingival hyperplasia: A report of two cases

Journal of Clinical and Scientific Research, 2022
Drugs associated with gingival overgrowth fall into three broad categories – anticonvulsants, immune suppressants and calcium channel blockers. Amlodipine is a third-generation dihydropyridine. The prevalence of amlodipine-induced gingival hyperplasia is
G Sri Lakshmi, G Tejaswini, B Alekhya, Maria Bethasaida Manuel, R Ram, V Siva Kumar   +5 more
doaj   +1 more source

Drug treatment of hypertension: focus on vascular health [PDF]

, 2016
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C., Lang, Ninian N., Touyz, Rhian M.   +2 more
core   +1 more source

Investigation of forced and total degradation products of amlodipine besylate by liquid chromatography and liquid chromatography-mass spectrometry [PDF]

Chemical Industry and Chemical Engineering Quarterly, 2014
An isocratic, reversed-phase liquid chromatographic method was applied for the investigation of the degradation products of amlodipine besylate under the stressed conditions in solution. Amlodipine besylate stock solutions were subjected to acid
Stoiljković Zora Ž., Jadranin Milka B., Đurić Svetlana Lj., Petrović Slobodan D., Ivić Avramov Milka L., Mijin Dušan Ž.   +5 more
doaj   +1 more source